- ICH GCP
- Rejestr badań klinicznych w USA
- Badanie kliniczne NCT07613151
Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study (NAPOLI)
NAPOLI: Negative/Low Hormone Receptor And/or HER2 POsitive Lobular Invasive Breast Carcinoma - A Real-World International Cohort Study
Przegląd badań
Status
Warunki
Szczegółowy opis
Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer (BC), accounting for approximately 10-15% of all invasive BCs. ILC is characterized by loss or dysfunction of the E-cadherin/catenin adhesion complex, typically due to CDH1 alterations, and by a distinctive discohesive and infiltrative growth pattern. These features translate into specific and unique biological, clinical and therapeutic challenges compared with invasive carcinoma of no-special type (IC-NST).
The majority of ILCs - up to 90% - are estrogen receptor (ER)-positive, progesterone receptor (PR)-positive and HER2-negative. In contrast, hormone receptor (HR)-negative ILC (ER and PR expression <1%), HR-low ILC (1-10% HR-positive cells), and HER2-positive (any HR expression) ILC are rare, biologically and clinically heterogeneous, and markedly underrepresented in clinical trials and large translational datasets. Moreover, the absence or very low expression of hormone receptors limits the role of endocrine therapy, thereby narrowing therapeutic options and potentially affecting prognosis. The efficacy of anti-HER2 therapies in ILC remains less defined than in IC-NST, due to the rarity of HER2 overexpression in breast cancer of lobular histotype (<10% of all ILC). Consequently, clinical outcomes and response to neoadjuvant therapies across both HR-positive/HER2-positive and HR-negative/HER2-positive represent an area where clinical data are lacking.
Recent genomic and transcriptomic studies have identified alterations involving pathways such as CDH1, ERBB2, TP53, PI3K/AKT/PTEN, and DNA damage response pathways, along with other potentially actionable molecular mechanisms. These findings suggest that HR-negative/low ILC may constitute a biologically distinct entity rather than simply an uncommon variant of conventional HR-positive lobular carcinoma, raising important questions regarding prognosis, optimal treatment sequencing, indications and response to neoadjuvant therapies, and the potential role of targeted and biomarker-driven treatments.
Triple-negative ILC (TN-ILC) is exceedingly rare, accounting for approximately 1-2% of all ILC and well below 1% of all invasive BCs, which largely explains their marked underrepresentation in prospective trials, and the consequent lack of disease-specific evidence to guide clinical management. Available evidence suggests that TN-ILC is not simply the lobular counterpart of conventional basal-like triple-negative BC. Indeed, when profiled by PAM50, the majority of TN-ILC are non-basal-like, in contrast to conventional TN IC-NST. Moreover, TN-ILC appears enriched for older age at diagnosis, pleomorphic and apocrine/histiocytoid morphology, androgen receptor (AR) expression, and luminal androgen receptor (LAR)-like biology. Importantly, TN-ILC has been reported to show poor responsiveness to conventional neoadjuvant chemotherapy despite aggressive clinical behavior, raising questions about the optimal systemic treatment strategy and the potential value of biomarker-driven approaches. The few dedicated series available consistently report an unfavorable course, with a pooled pathologic complete response (PCR) rate of approximately 22.5%: in the largest early-stage cohort described to date, 5- and 10-year invasive disease-free survival were only approximately 50% and 37%, respectively. In addition, potentially actionable ERBB2 mutations have been reported in up to ~20% of TN-ILC and, together with frequent enrichment in DNA-damage-response, recurrent ESRRA mutations and PI3K/AKT/PTEN pathway alterations, may represent tractable therapeutic vulnerabilities, including HER2 tyrosine-kinase inhibitors, PARP or PI3K/AKT inhibitors.
HER2-positive ILC represents another uncommon and clinically relevant subgroup. HER2 overexpression/amplification in ILC is more frequently observed in pleomorphic and high-grade variants, and may be associated with distinct clinicopathologic features, higher proliferative activity and worse prognosis than classic HR-positive/HER2-negative ILC. However, data specific to HER2-positive ILC remain sparse, and most recommendations are extrapolated from IC-NST cohorts. Whether patterns of response to anti-HER2 neoadjuvant therapy, rates of PCR, surgical outcomes and recurrence patterns differ from those observed in IC-NST remains insufficiently defined.
Apocrine differentiation in the lobular setting is of particular interest, as it represents a rare and potentially distinct phenotype, commonly associated with HR negativity, AR expression, HER2 pathway activation in a subset of cases, luminal androgen receptor (LAR) biology, and unique genomic alterations, thereby providing a biological rationale for AR-directed or other targeted therapeutic strategies. In the lobular setting, apocrine, pleomorphic and histiocytoid features may overlap morphologically and biologically. However, the true prevalence, genomic correlates, treatment patterns and outcomes of apocrine lobular tumors remain poorly characterized. In the ductal setting TN apocrine carcinomas have shown markedly low PCR rates to neoadjuvant chemotherapy (as low as ~7%, versus ~30% in non-apocrine TN BC), and LAR-subtype tumors achieve the lowest PCR across TN subtypes (~14% versus ~43%). As apocrine and LAR features are enriched in HR-negative/low ILC, comparably low chemosensitivity is expected in this setting, further supporting a dedicated, biomarker-driven therapeutic approach.
Because of the rarity of these subtypes, prospective randomized studies are unlikely to be carried out in the near future. A large international real-world cohort is therefore needed to clarify whether HR-negative/low ILC, apocrine/LAR-enriched lobular tumors and HER2-positive ILC represent clinically meaningful and biologically distinct entities, and to identify potential prognostic and predictive biomarkers.
The NAPOLI study is designed to assemble a large international cohort of patients with HR-negative/low and/or HER2-positive ILC, with a special focus on apocrine/LAR features, molecular alterations, imaging presentation, multidisciplinary treatment patterns, response to neoadjuvant therapies, surgical and axillary management, recurrence patterns, and oncologic outcomes. The overarching aim is to generate disease-specific evidence to improve risk stratification, identify clinically relevant prognostic and predictive biomarkers, guide multidisciplinary management (i.e. the use of neoadjuvant chemotherapy) and support future translational and biomarker-driven studies in this rare and underexplored subgroup of BC.
Typ studiów
Zapisy (Szacowany)
Kontakty i lokalizacje
Kontakt w sprawie studiów
- Nazwa: Massimo Ferrucci, MD PhD
- Numer telefonu: 049 821 5500
- E-mail: massimoferrucci@gmail.com
Kopia zapasowa kontaktu do badania
- Nazwa: Daniele Passeri, MD
- Numer telefonu: +39 333 383 9397
- E-mail: daniele.passeri.1995@gmail.com
Lokalizacje studiów
-
-
-
Padova, Włochy
- Rekrutacyjny
- Veneto Institute of Oncology
-
Kontakt:
- Massimo Ferrucci, MD PhD
- Numer telefonu: 049 821 5500
- E-mail: massimoferrucci@gmail.com
-
Kontakt:
- Daniele Passeri, MD
- Numer telefonu: +393333839397
- E-mail: daniele.passeri.1995@gmail.com
-
Pod-śledczy:
- Francesco Milardi
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Wiek uprawniający do nauki
- Dorosły
- Starszy dorosły
Akceptuje zdrowych ochotników
Metoda próbkowania
Badana populacja
Opis
Inclusion Criteria:
- Female or male patients aged ≥18 years;
- Histologically confirmed ILC, confirmed by E-cadherin loss/aberrant expression and/or p120 cytoplasmic relocalization and/or CDH1 alteration;
- HR-negative (ER <1% and PR <1%) or HR-low (ER and/or PR 1-10%) disease, as defined by ASCO/CAP guidelines, is eligible regardless of HER2 status (assessed according to 2025 ASCO/CAP criteria, with HER2-low and HER2-ultralow status recorded where assessable);
- HR-positive (ER>10% according to the ASCO/CAP guidelines) ILC is eligible only if HER2 status is positive;
- Mixed ductal-lobular carcinomas are eligible provided that a clearly identified invasive lobular component is present and predominant (>50% lobular) and HR-negative/low criteria are met;
- Stage I-III disease at diagnosis; Patients with de novo stage IV disease who underwent surgery of the primary tumor will not be included in the main study cohort but may be captured in a separate exploratory cohort for dedicated analysis;
- Patients who underwent surgery of the primary tumor at the participating institution, either upfront or after neoadjuvant systemic treatment;
- Diagnosis occurred between 1 January 2000 and 31 December 2025;
- Minimum follow-up of 12 months for patients without an event, unless recurrence or death occurred earlier;
- Local review by a dedicated breast pathologist to confirm the diagnosis and the related molecular features, with particular attention to the confirmation of apocrine morphology.
Exclusion Criteria:
- Pure IC NST without any lobular invasive component;
- ER or PR expression >10% in the invasive component, in cases with negative HER2 status;
- In situ lobular neoplasia (lobular carcinoma in situ) without an invasive component;
- De novo stage IV disease (such patients, if they underwent surgery of the primary tumor, will be captured in a separate exploratory cohort for a dedicated analysis)
- Synchronous invasive BC of another dominant histology requiring systemic treatment that precludes attribution of outcomes to HR-negative/low ILC;
- Prior invasive BC under active systemic treatment at the time of diagnosis, unless clearly documented as unrelated and not expected to confound outcomes;
- Insufficient data or follow up
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
Kohorty i interwencje
Grupa / Kohorta |
Interwencja / Leczenie |
|---|---|
|
Triple-negative ILC
ER <1%, PR <1% and HER2-negative (IHC 0, 1+, or 2+ with negative ISH).
Within this cohort, HER2 expression will be further categorized, where assessable, as HER2 null (IHC 0, no staining), HER2-ultralow (IHC 0+ with faint/incomplete staining in ≤10% of tumor cells) and HER2-low (IHC 1+, or 2+/ISH-negative).
|
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
|
|
HER2-positive ILC
HER2-positive disease, defined as IHC 3+ or IHC 2+ ISH-positive.
Subgroups within this cohort will include HR-negative ILC (ER and PR both <1%) and HR-positive (ER>10%) HER2-positive ILC.
|
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
|
|
HR-low ILC (cross-cutting category)
ER and/or PR 1-10%, with neither receptor >10%, analyzed separately as a distinct group and also within the HER2-defined groups.
|
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
|
|
Exploratory Subgroups (cross-cutting category)
Apocrine and/or LAR-featured ILC, and non-classic lobular variants (pleomorphic, histiocytoid and other rare histologic variants).
|
Upfront Conservative or Demolitive Breast Surgery
Adjuvant Breast or Chest Wall Radiotherapy after Breast Surgery
Adjuvant or Neoadjuvant Endocrine Therapy
Adjuvant or Neoadjuvant Chemotherapy
|
Co mierzy badanie?
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Invasive disease-free survival (iDFS)
Ramy czasowe: Through study completion, an average of 5 years
|
Time from definitive surgery to first invasive event (ipsilateral invasive, locoregional invasive, or distant recurrence, contralateral invasive BC)
|
Through study completion, an average of 5 years
|
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Overall survival (OS)
Ramy czasowe: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
|
|
Distant disease-free survival (DDFS)
Ramy czasowe: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
|
|
Breast cancer-specific survival (BCSS)
Ramy czasowe: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
|
|
Locoregional recurrence-free survival (LRRFS)
Ramy czasowe: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
|
|
Recurrence rate and patterns
Ramy czasowe: Through study completion, an average of 5 years
|
Local, regional, distant, contralateral, and site-specific distant (including ILC-enriched sites)
|
Through study completion, an average of 5 years
|
Inne miary wyników
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Pathologic complete response (pCR) - ypT0/Tis ypN0, with residual cancer burden (RCB) class distribution; in the neoadjuvant cohort, event-free survival (EFS) from treatment initiation where data permit
Ramy czasowe: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
|
|
Multidisciplinary treatment patterns and treatment-related outcomes according to therapeutic strategy (upfront surgery versus neoadjuvant treatment), surgical management (including reconstruction/oncoplastic approaches), systemic and radiation therapy
Ramy czasowe: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
|
|
Prognostic, predictive and potential therapeutic relevance of clinicopathologic, molecular, and biologic features
Ramy czasowe: Through study completion, an average of 5 years
|
Somatic and germline alterations, TME features (stromal TILs, PD-L1 status, immune-related biomarkers), apocrine differentiation, LAR phenotype, HER2 status, HR-negative versus HR-low status, and classic versus pleomorphic/non-classic ILC variants
|
Through study completion, an average of 5 years
|
|
Biomarker-outcome associations with iDFS, pCR and OS
Ramy czasowe: Through study completion, an average of 5 years
|
Through study completion, an average of 5 years
|
Współpracownicy i badacze
Sponsor
Śledczy
- Krzesło do nauki: Francesco Milardi, MD, Veneto Institute of Oncology IRCCS
Publikacje i pomocne linki
Publikacje ogólne
- Niemeier LA, Dabbs DJ, Beriwal S, Striebel JM, Bhargava R. Androgen receptor in breast cancer: expression in estrogen receptor-positive tumors and in estrogen receptor-negative tumors with apocrine differentiation. Mod Pathol. 2010 Feb;23(2):205-12. doi: 10.1038/modpathol.2009.159. Epub 2009 Nov 6.
- Vranic S, Feldman R, Gatalica Z. Apocrine carcinoma of the breast: A brief update on the molecular features and targetable biomarkers. Bosn J Basic Med Sci. 2017 Feb 21;17(1):9-11. doi: 10.17305/bjbms.2016.1811.
- Van Baelen K, Nguyen HL, Richard F, Zels G, Karsten MM, Nader-Marta G, Vermeulen P, Dirix L, Dordevic AD, de Azambuja E, Larsimont D, Maetens M, Biganzoli E, Wildiers H, Smeets A, Nevelsteen I, Neven P, Floris G, Desmedt C. Association of HER2-low with clinicopathological features in patients with early invasive lobular breast cancer: an international multicentric study. Breast Cancer Res. 2025 Jun 13;27(1):106. doi: 10.1186/s13058-025-02058-x.
- Lehmann BD, Bauer JA, Schafer JM, Pendleton CS, Tang L, Johnson KC, Chen X, Balko JM, Gomez H, Arteaga CL, Mills GB, Sanders ME, Pietenpol JA. PIK3CA mutations in androgen receptor-positive triple negative breast cancer confer sensitivity to the combination of PI3K and androgen receptor inhibitors. Breast Cancer Res. 2014 Aug 8;16(4):406. doi: 10.1186/s13058-014-0406-x.
- Aktas A, Gurleyik MG, Akkus D, Ucur Z, Aker F. Invasive lobular breast carcinoma variants; clinicopathological features and patient outcomes. Breast Cancer Res Treat. 2025 Jul;212(2):347-359. doi: 10.1007/s10549-025-07729-z. Epub 2025 May 21.
- Borella F, Gallio N, Giurdanella M, Capella G, Cassoni P, Castellano I. Triple-negative lobular breast cancer: focus on pathology and clinical challenges. Hum Pathol. 2025 Aug;162:105871. doi: 10.1016/j.humpath.2025.105871. Epub 2025 Jul 8.
- Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, Hayes DF, Lakhani SR, Chavez-MacGregor M, Perlmutter J, Perou CM, Regan MM, Rimm DL, Symmans WF, Torlakovic EE, Varella L, Viale G, Weisberg TF, McShane LM, Wolff AC. Estrogen and Progesterone Receptor Testing in Breast Cancer: ASCO/CAP Guideline Update. J Clin Oncol. 2020 Apr 20;38(12):1346-1366. doi: 10.1200/JCO.19.02309. Epub 2020 Jan 13.
- Conforti F, Pala L, Pagan E, Rocco EG, Bagnardi V, Montagna E, Peruzzotti G, De Pas T, Fumagalli C, Pileggi S, Pesenti C, Marchini S, Corso G, Marchio' C, Sapino A, Graffeo R, Collet L, Aftimos P, Sotiriou C, Piccart M, Gelber RD, Viale G, Colleoni M, Goldhirsch A. Biological and clinical features of triple negative Invasive Lobular Carcinomas of the breast. Clinical outcome and actionable molecular alterations. Breast. 2021 Oct;59:94-101. doi: 10.1016/j.breast.2021.06.011. Epub 2021 Jun 26.
- Taniguchi K, Takada S, Omori M, Igawa T, Nishimura MF, Morito T, Ichimura K, Yoshino T. Triple-negative pleomorphic lobular carcinoma and expression of androgen receptor: Personal case series and review of the literature. PLoS One. 2020 Jul 22;15(7):e0235790. doi: 10.1371/journal.pone.0235790. eCollection 2020.
- He L, Araj E, Peng Y. HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features. Curr Oncol. 2021 Apr 24;28(3):1608-1617. doi: 10.3390/curroncol28030150.
- Sidhu S, Kaur G, Singh A, et al. Androgen receptor expression in estrogen receptor and progesterone receptor negative breast cancers and its clinicopathological significance. J Lab Physicians. 2023;15(4):573-579.
- Anjum S, Ahmad F, Islam N, et al. Apocrine lesions of breast and invasive carcinoma with apocrine differentiation: a brief review. Egypt J Radiol Nucl Med. 2023;54:164.
- Corso G, Shen S, Criscitiello C, Mukhtar R, Gamble L, Rocco EG, Pesapane F, Nicosia L, Jhaveri K, Salimbeni BT, Massari G, Meduri E, De Scalzi AM, Concardi A, Magnoni F, Mamtani A, Pareja F, Leonardi MC, Sacchini V, Bogani G, Vecchia C, Presti D, Colleoni MA, Veronesi P, Robson ME. Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group. Cancer Treat Rev. 2025 Nov;140:103001. doi: 10.1016/j.ctrv.2025.103001. Epub 2025 Aug 7.
- Oesterreich S, Nasrazadani A, Zou J, Carleton N, Onger T, Wright MD, Li Y, Demanelis K, Ramaswamy B, Tseng G, Lee AV, Williams N, Kruse M. Clinicopathological Features and Outcomes Comparing Patients With Invasive Ductal and Lobular Breast Cancer. J Natl Cancer Inst. 2022 Nov 14;114(11):1511-1522. doi: 10.1093/jnci/djac157.
- Bergeron A, MacGrogan G, Bertaut A, Ladoire S, Arveux P, Desmoulins I, Bonnefoi H, Loustalot C, Auriol S, Beltjens F, Degrolard-Courcet E, Charon-Barra C, Richard C, Boidot R, Arnould L. Triple-negative breast lobular carcinoma: a luminal androgen receptor carcinoma with specific ESRRA mutations. Mod Pathol. 2021 Jul;34(7):1282-1296. doi: 10.1038/s41379-021-00742-9. Epub 2021 Mar 22.
- Batra H, Mouabbi JA, Ding Q, Sahin AA, Raso MG. Lobular Carcinoma of the Breast: A Comprehensive Review with Translational Insights. Cancers (Basel). 2023 Nov 20;15(22):5491. doi: 10.3390/cancers15225491.
- Barroso-Sousa R, Metzger-Filho O. Differences between invasive lobular and invasive ductal carcinoma of the breast: results and therapeutic implications. Ther Adv Med Oncol. 2016 Jul;8(4):261-6. doi: 10.1177/1758834016644156. Epub 2016 Apr 25.
Przydatne linki
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Zakończenie podstawowe (Szacowany)
Ukończenie studiów (Szacowany)
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Nowotwory według lokalizacji
- Nowotwory według typu histologicznego
- Nowotwory gruczołowe i nabłonkowe
- Rak gruczołowy
- Choroby skórne
- Choroby piersi
- Rak
- Nowotwory, przewodowe, zrazikowe i rdzeniaste
- Nowotwory piersi
- Choroby skóry i tkanki łącznej
- Nowotwory
- Rak, zrazikowy
- Lecznictwo
- Radioterapia
- Łączna terapia modalności
- Terapia lecznicza
- Radioterapia, adiuwant
Inne numery identyfikacyjne badania
- CESC IOV 2023-61
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .